市場調查報告書
商品編碼
1468398
2024-2032年按藥物類型(化療、生物療法、荷爾蒙療法等)、配銷通路(醫院藥房、藥房和零售藥房、線上藥房)和地區分類的前列腺癌治療市場報告Prostate Cancer Treatment Market Report by Drug Type (Chemotherapy, Biological Therapy, Hormone Therapy, and Others), Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies), and Region 2024-2032 |
IMARC Group年,全球前列腺癌治療市場規模達77億美元。
前列腺癌是一種嚴重的惡性腫瘤,是由男性前列腺內的各種異常細胞無法控制的分裂和擴張引起的。它可以透過使用各種療法來治療,例如疫苗、藥物和治療。其中,化療、免疫療法、冷凍療法、手術、荷爾蒙療法、標靶療法和放射療法是一些最常見的治療類型,有助於減輕癌細胞在體內的擴散。這些治療是根據各種評估提供給患者的,例如患者的年齡、所經歷症狀的嚴重程度、醫療狀況和既往健康史。
攝護腺癌的盛行率不斷上升,特別是在不斷增加的老年人口中,是目前推動市場成長的主要因素之一。與此一致的是,有利的醫療報銷政策的可用性以及一些國家的政府機構為引入患者援助計劃(PAP)而採取的眾多舉措正在成為其他成長誘導因素。 PAP 是一項有組織的計劃,由製藥公司控制,透過提供免費治療藥物來向患者提供經濟援助。此外,重大技術進步,例如將多參數磁振造影(mp-MRI)設備與非轉移性去勢抗性(nmCRPC)和轉移性荷爾蒙天然(mHNPC)設定相結合,用於早期檢測前列腺癌,同時減輕診斷錯誤,也促進了市場的成長。此外,為引進新型治療產品而對研發(R&D)活動進行的廣泛投資,以及這些產品在各種線上和線下配銷通路上的便捷獲取,正在為市場創造積極的前景。
The global prostate cancer treatment market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.
Prostate cancer is a type of severe malignant tumor, which is caused by the uncontrollable division and expansion of various abnormal cells in the prostate gland present in men. It can be treated through the use of various therapeutics, such as vaccines, medications, and treatments. Amongst these, chemotherapy, immunotherapy, cryotherapy, surgery, hormonal, targeted and radiation therapy are some of the most common treatment types that aid in mitigating the spread of cancer cells in the body. These therapies are provided to the patient based on various assessments, such as the age of the patient, severity of the symptoms experienced, medical condition, and previous health history.
The increasing prevalence of prostate cancer, especially amongst the rising geriatric population, is one of the prime factors currently driving the market toward growth. In line with this, the availability of favorable medical reimbursement policies and the numerous initiatives being undertaken by the government bodies of several countries for introducing patient assistance programs (PAPs) are acting as other growth-inducing factors. PAP is an organized program, which is controlled by pharmaceutical companies for providing financial assistance to patients by offering free medications for treatment purposes. Moreover, significant technological advancements, such as the integration of multiparametric-magnetic resonance imaging (mp-MRI) devices with non-metastatic castration-resistant (nmCRPC) and metastatic hormone nave (mHNPC) settings for detecting prostate cancer at early stages, while mitigating diagnostic errors, is also contributing to the market growth. Additionally, extensive investments in the research and development (R&D) activities to introduce novel therapeutic products, along with their easy availability across various online and offline distribution channels, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global prostate cancer treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug type and distribution channel.
Chemotherapy
Biological Therapy
Hormone Therapy
Others
Hospitals Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., AstraZeneca plc, Bayer Aktiengesellschaft, Dendreon Pharmaceuticals LLC. (Sanpower Group Co. Ltd.), F. Hoffmann-La Roche AG, Ferring B.V., GlaxoSmithKline Plc, Ipsen (Mayroy SA), Novartis International AG, Takeda Pharmaceutical Company Ltd. and Tolmar Pharmaceuticals Inc.